

Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease)

NCT07340723

Status	RECRUITING
Phase	Phase 2
Sponsor	Daihong Liu
Enrollment	168 participants

Key Eligibility Criteria

Inclusion (3)

- Diagnosed with hematological diseases.
- Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies.
- New onset of grade II acute GVHD or intermediate or high risk aGVHD (based on modified GVHD Glucksberg criteria) within 100 days post-transplantation.

Exclusion (17)

- Recipients of second allogeneic stem cell transplant.
- Acute GVHD induced by donor lymphocyte infusion, interferon.
- Received first line aGVHD treatment before enrollment.
- Overlap GVHD syndrome.
- Pregnant or breast-feeding women.

... and 12 more (see full listing online)

Locations (1 total)

Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, Beijing Municipality, China